BrightEdge — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Machine learning and data platform for understanding how diseases fight back and resist therapies
David Li(Founder)in
Co-investorsHAWKTAILJude GomilaValkyrieAxial VCHOF CapitalObvious Ventures+3 more
Naveris develops and commercializes liquid biopsy tests for the early detection and monitoring of HPV-associated cancers, particularly head and neck and anal cancers.
BiotechData & InfrastructureDigital HealthHealthtechMedical DevicesWaltham, US
James McNally(Executive Officer, Director)inPiyush Gupta(Executive Officer, Director)
BoardAnne Stone(Director)Francis Crispino(Director)Philip Grahame Haydon(Director)
Co-investorsGurnet Point CapitalTechU Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.







